Twelve cases of glottic carcinoma in situ treated by radiotheraphy: an observation on clinical course versus response

1993 ◽  
Vol 107 (11) ◽  
pp. 1014-1016 ◽  
Author(s):  
J. P. Brooks ◽  
D. W. Morgan ◽  
J. Glaholm
Keyword(s):  
Carcinoma In Situ ◽  
Clinical Course ◽  
Alternative Methods ◽  
Glottic Carcinoma ◽  
Methods Of Treatment ◽  
Disease Free ◽  
Long Term Studies

AbstractCarcinoma in Situ (CIS) of the glottis is an uncommon and poorly understood condition with few, large, long- term studies. Twelve cases are presented which were treated with radiotherapy. At three-year follow-up all the patients are disease free and in 83 per cent the mucosa has returned to normal. The alternative methods of treatment are discussed.

LONG-TERM FOLLOW-UP OF PATIENTS WITH CARCINOMA IN SITU OF THE URINARY BLADDER

1999 ◽  
pp. 116
Author(s):  
Roxann M. Neumann ◽  
Liang Cheng ◽  
John C. Cheville ◽  
Bradley C. Leibovich ◽  
Bruce E. Spotts ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Carcinoma In Situ ◽  
Long Term Follow Up

Laryngeal Dysplasia: Epidemiology and Treatment Outcome

1995 ◽  
Vol 104 (8) ◽  
pp. 596-602 ◽  
Author(s):  
Keith E. Blackwell ◽  
Thomas C. Calcaterra ◽  
Yao-Shi Fu
Keyword(s):  
Treatment Group ◽  
Carcinoma In Situ ◽  
Invasive Carcinoma ◽  
Endoscopic Therapy ◽  
Partial Laryngectomy ◽  
Severe Dysplasia ◽  
Long Term Follow Up

A retrospective analysis was undertaken of 65 patients with long-term follow-up for laryngeal squamous dysplasia. Based on the degree of dysplasia demonstrated on initial biopsy, 0 of 6 patients showing hyperkeratosis without dysplasia, 3 of 26 patients (12%) showing mild dysplasia, 5 of 15 patients (33%) showing moderate dysplasia, 4 of 9 patients (44%) showing severe dysplasia, and 1 of 9 patients (11%) showing carcinoma in situ eventually progressed to invasive carcinoma. An analysis was made of the impact of various treatment modalities in 33 patients demonstrating moderate dysplasia, severe dysplasia, or carcinoma in situ. Invasive carcinoma developed in 10 of 21 patients (48%) treated endoscopically and 0 of 12 patients treated by more aggressive therapy, including external beam radiotherapy, partial laryngectomy, or total laryngectomy. Of the patients in the endoscopic therapy group who developed invasive carcinoma, all were salvaged successfully. The overall rate of laryngeal preservation was 15 of 21 patients (71%) in the endoscopic treatment group and 11 of 12 patients (92%) in the aggressive treatment group. This difference is not statistically significant. We conclude that there is a moderately high rate of progression to invasive carcinoma in patients undergoing repeated endoscopic therapy for intraepithelial neoplasms of the larynx. However, with close, long-term follow-up, patients undergoing endoscopic therapy have an overall outcome similar to that in patients treated with partial laryngectomy or radiotherapy prior to developing invasive disease.

Long-Term Follow-up of Lobular Neoplasia (Atypical Lobular Hyperplasia/Lobular Carcinoma In Situ) Diagnosed on Core Needle Biopsy

2012 ◽  
Vol 19 (10) ◽  
pp. 3131-3138 ◽  
Author(s):  
Miraj G. Shah-Khan ◽  
Xochiquetzal J. Geiger ◽  
Carol Reynolds ◽  
James W. Jakub ◽  
Elizabeth R. DePeri ◽  
...  
Keyword(s):  
Needle Biopsy ◽  
Carcinoma In Situ ◽  
Lobular Carcinoma ◽  
Lobular Carcinoma In Situ ◽  
Core Needle ◽  
Atypical Lobular Hyperplasia ◽  
Long Term Follow Up

Carcinoma in Situ of the Glottis: Radiotherapy or Excision Biopsy?

1993 ◽  
Vol 102 (8) ◽  
pp. 592-595 ◽  
Author(s):  
George E. Murty ◽  
Joseph P. Diver ◽  
Patrick J. Bradley
Keyword(s):  
Carcinoma In Situ ◽  
Excision Biopsy ◽  
First Year ◽  
Glottic Carcinoma ◽  
First Line ◽  
Laryngeal Function ◽  
Primary Radiotherapy ◽  
Laser Excision

Excision biopsy, radiotherapy, and laryngofissure cordectomy have all been used, but the best treatment regimen for glottic carcinoma in situ remains controversial. A 20-year experience of 37 cases is reported. For the first 10 years biopsy with radiotherapy was the first-line treatment (n = 20), but for the last 10 years surgical or laser excision biopsy alone has been performed (n = 17). The T stage of the carcinoma in situ does not determine its premalignant potential. Malignancy appears to be a recurrence, rather than a new expression of carcinogenesis. Excision biopsy alone provides local control results (75%) comparable to those of primary radiotherapy (85%). Excision biopsy alone, however, retains the option of subsequent radiotherapy with preservation of laryngeal function, but very close follow-up, especially in the first year, is required.

scholarly journals Long-term Follow-up of Pure Ductal Carcinoma in situ after Breast-Conserving Surgery

2019 ◽  
Vol 7 (2) ◽  
pp. 73-80
Author(s):  
Keong Won Yun ◽  
Jisun Kim ◽  
Jong Won Lee ◽  
Sae Byul Lee ◽  
Hee Jeong Kim ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Breast Conserving Surgery ◽  
Long Term Follow Up

Transoral Laser Surgery for Early Glottic Carcinoma: A Single Surgeon Experience of 101 Consecutive Cases

ORL ◽  
2020 ◽  
pp. 1-6
Author(s):  
Kerem Ozturk ◽  
Goksel Turhal
Keyword(s):  
Overall Survival ◽  
Carcinoma In Situ ◽  
Early Stage ◽  
Case Series ◽  
Disease Free Survival ◽  
Glottic Carcinoma ◽  
Free Survival ◽  
Surgeon Experience ◽  
Disease Free

<b><i>Purpose:</i></b> Investigate the clinical and oncological results of early-stage glottic laryngeal carcinoma patients performed by a single surgeon. <b><i>Methods:</i></b> This study was carried out at a tertiary academic center. A total of 101 patients were included (92 males [91.1%], 9 females [8.9%]). Mean age was 62.98 ± 10.2 years (range 33–87). Recurrence, disease-free survival, overall survival, laryngeal preservation rates were analyzed. <b><i>Results:</i></b> Tumor stage was Tis (carcinoma in situ) in 11 patients (10.9%), T1a in 66 patients (65.3%), T1b in 12 patients (11.9%), and T2 in 12 patients (11.9%). Postoperative pathology was squamous cell carcinoma in 69 patients (68.3%), carcinoma in situ in 26 patients (25.7%), and high-grade dysplasia in 6 patients (5.9%). Five patients (5.0%) underwent type 1, 7 (6.9%) type 2, 45 (44.6%) type 3, 24 (23.8%) type 4, 6 (5.9%) type 5a, 8 (7.9%) type 5c, 4 (4.0%) type 5d, and 2 (2.0%) type 6 cordectomy. Median follow-up time was 30 months (range 14–66). There were 5 recurrences (5.0%). Three-year disease-free survival was 94.4%. Three-year disease-free survival for stage I and II patients was 94.9 and 91.7%, respectively. Overall survival was 93.8%. Only 1 patient died related to cardiovascular disease. Disease-specific survival was 100%. <b><i>Conclusions:</i></b> In conclusion, this is a large case series with good oncological outcomes presented with the perspective of a single surgeon. The data of the study is in accordance with the previous reports.

External accelerated partial breast irradiation for ductal carcinoma in situ: long-term follow-up from a phase 3 randomized trial

2018 ◽  
Vol 105 (3) ◽  
pp. 205-209 ◽  
Author(s):  
Carlotta Becherini ◽  
Icro Meattini ◽  
Lorenzo Livi ◽  
Pietro Garlatti ◽  
Isacco Desideri ◽  
...  
Keyword(s):  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Accelerated Partial Breast Irradiation ◽  
Partial Breast Irradiation ◽  
Efficacy And Safety ◽  
Breast Irradiation ◽  
Phase 3

Introduction: For a long time, accelerated partial breast irradiation (APBI) effectiveness for ductal carcinoma in situ (DCIS) has been debated, due to conflicting published results. Recent encouraging data from phase 3 trials reopened new perspectives for this radiation approach. The aim of the present study was to analyze the long-term efficacy and safety results of the series of patients with DCIS enrolled in the APBI arm of the APBI-IMRT-Florence phase 3 trial (NCT02104895). Methods: Patients were treated in a phase 3 randomized trial comparing whole breast irradiation (50 Gy in 25 fractions to the whole breast, plus 10 Gy in 5 fractions to the tumor bed) to APBI (30 Gy in 5 nonconsecutive fractions) using the intensity-modulated radiotherapy technique. Results: Overall, 22 patients were treated in the APBI arm. Median age was 62 years (mean 59; range 42–75 years). At a median follow-up of 9.2 years (mean 8.8; range 3.8–12.1 years), no contralateral invasive/DCIS occurrence, distant metastasis, or breast cancer–related death were recorded. The 5- and 10-year local recurrence, distant metastasis–free survival, and breast cancer–specific survival were 100%. The 10-year overall survival rate was 90.9%. No late toxicity at 5 and 10 years was recorded. Conclusions: Waiting for pending studies and mature follow-up, we confirmed the efficacy and safety of APBI for low-risk DCIS.

scholarly journals Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery

Cancer ◽  
1999 ◽  
Vol 86 (9) ◽  
pp. 1757-1767 ◽  
Author(s):  
Kimberly J. Van Zee ◽  
Laura Liberman ◽  
Billur Samli ◽  
Katherine N. Tran ◽  
Beryl McCormick ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Breast Conserving Surgery ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document